MedTrace Logo

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

NCT02726789 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-05-08

Study results available
· View outcomes & findings →

Summary

The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already receiving entecavir and continuing entecavir with treatment.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

REP 2139-Ca

the nucleic acid polymer REP 2139 formulated as a calcium chelate complex

DRUG

pegylated interferon

immunotherapy

DRUG

entecavir

local generic entecavir

Sponsors & Collaborators

  • Replicor Inc.

    lead INDUSTRY

Principal Investigators

  • Mamun Al-Mahtab, MD · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-09-30
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02726789 on ClinicalTrials.gov